Discontinuation of ZOLADEX Implant in Australia

Following the completion of government processes, the ZOLADEX 3.6mg implant will not be available on the PBS in Australia from November 2026. The ZOLADEX 3.6mg implant will not be available for patients to purchase via a private prescription from November 2026.

The ZOLADEX 10.8mg implant will remain available to Australian patients. The ZOLADEX ® (goserelin) 10.8mg implant is currently registered and reimbursed in Australia for eligible prostate cancer patients.

The discontinuation of ZOLADEX 3.6mg implant from the Australian market is a global decision to reduce the dose options available in some countries. This discontinuation is not related to the safety or efficacy of ZOLADEX. AstraZeneca has commenced engagement with the clinical community to minimise any potential disruption to patient care due to this change. AstraZeneca advised that if you have any patients treated with ZOLADEX (goserelin) 3.6mg implant, you begin planning transition to a suitable alternative.

AstraZeneca is preparing a government regulatory and reimbursement application to expand the indication for the ZOLADEX 10.8mg implant to include breast cancer patients that are hormone receptor positive.  

Please refer all questions to AstraZeneca’s Medical Information team on telephone 1800 805 342 or via https://contactazmedical.astrazeneca.com